Loss of nuclear ATRX immunoreactivity or identification of ATRX mutation differentiates IDH mutant astrocytoma from IDH mutant oligodendroglioma (Ikemura et al., 2016). Here, IDH2 is linked to astrocytoma (excluding glioblastoma).